Finance entity
All 1 tracked stories fall under one category: markets. JNJ-2113 is most often covered alongside Johnson & Johnson, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 2.8 for the broader beat in this window.
Last mentioned: Feb 25, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: markets. JNJ-2113 is most often covered alongside Johnson & Johnson, which appears in 1 of these 1 story. Each story carries 2 original sources on average, compared with 2.8 for the broader beat in this window. Their average consequence score of 6 runs above the beat's 5.7 for that window. We currently track 1 Finance story that mention JNJ-2113, all published on February 25, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 96 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering JNJ-2113. Shared-story counts are live from our verified record — not editorial picks.
Institutional Exit Revealed
13F filings reveal a $170 million divestment by a major institutional fund.
120% Gain Milestone
PTGX stock reaches a 120% gain milestone from its 52-week low.
J&J Partnership Milestone
Johnson & Johnson advances JNJ-2113 into late-stage trials, validating oral peptide tech.
Phase 3 Data Release
Positive Phase 3 data for rusfertide in polycythemia vera triggers initial stock rally.
Protagonist Therapeutics shares have soared 120% following clinical and regulatory milestones, but a recent $170 million institutional exit is raising questions about the stock's near-term ceiling. The move highlights a growing divergence between retail momentum and institutional profit-taking in the biotech sector.
JNJ-2113 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
